Found 14 articles
OnQuality Pharmaceuticals to Present Preclinical Data for OQL051, a Novel Chemotherapy-Induced Diarrhea Therapeutic, at AACR
OnQuality Pharmaceuticals ("OnQuality"), today announced it will be giving an oral presentation highlighting preclinical data for its therapeutic candidate OQL051, a gut-restricted CDK4/6 inhibitor for the prevention of chemotherapy-induced diarrhea (CID), at the American Association for Cancer Research (AACR) Annual Meeting 2022.
Clinical Catch-Up for February 21
OnQuality Pharmaceuticals to Present NOVA-II Phase 2 Trial Update and Oncologist Survey Demonstrating Oncodermatology Unmet Need at ASCO GU
OnQuality Pharmaceuticals ("OnQuality"), today announced it will be presenting two posters on Hand-Foot Skin Reaction (HFSR), including a Trial in Progress on its NOVA-II Phase 2 study and the results of an oncologist survey, at the American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO GU).
OnQuality Pharmaceuticals to Present Oncologist Survey Data Demonstrating Need for New Cancer Therapy-Associated Diarrhea Treatments at ASCO GI 2022
OnQuality Pharmaceuticals ("OnQuality"), today announced it will be presenting the results of an oncologist survey on willingness to use new medications to prevent or treat gastrointestinal side effects of cancer therapies in a poster at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
1/10/2022BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade.
1/10/2022The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.
OnQuality Pharmaceuticals Reports Topline Data from Phase 2 Trial of Treatment for Cancer Therapy Induced Skin Toxicity that Met Expectations
OnQuality Pharmaceuticals ("OnQuality"), today announced that Part 1 of the Phase 2 NOVA-II clinical trial evaluating OQL011 met the company's expectations of safety, efficacy and the patient reported outcome of Hand-Foot Skin Reaction (HFSR)-related pain.
OnQuality Pharmaceuticals today announced the completion of part 1 of the NOVA-II Phase 2 trial evaluating OQL011, a topical ointment to treat cancer therapy-induced skin toxicities.
OnQuality Pharmaceuticals ("OnQuality"), today announced that it has been selected to deliver a company presentation at the Biotechnology Innovation Organization (BIO)'s 2021 BIO Digital International Convention.
OnQuality Pharmaceuticals to Present on NOVA-II Trial Evaluating OQL011 at the 2021 ASCO and MASCC/ISOO Annual Meetings
OnQuality Pharmaceuticals today announced that abstracts for the NOVA-II clinical trial evaluating OnQuality's lead candidate, OQL011, have been selected for presentations at two upcoming meetings: a Trial in Progress poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting,
April springs up with showers of cash for these life sciences companies.
The trial assesses the safety and efficacy of a targeted supportive care agent that addresses the specific side effects of vascular endothelial growth factor receptor (VEGFR) inhibitors among cancer patients.
- Financing enables OnQuality to continue the development of targeted cancer supportive care products - Pharmaceutical leader Michael McCullar, Ph.D., MBA, joins the company as Chief Executive Officer
According to the report, the global sterilization services market was valued at US$ 3.1Bn in 2018 and is projected to expand at a CAGR of ~7% from 2019 to 2027. Sterilization service providers offer sterilization of various supplies such as medical devices, instruments, pharmaceuticals, and other products.